Dudediligence.

Foghorn Therapeutics Inc

FHTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$7.8MSep ’24$2.9MDec ’24$6.0MMar ’25$7.6MJun ’25$8.2MSep ’25$9.2MDec ’25$3.3MMar ’26$16.1MJun ’26
Net income, by quarter
−$19.1MSep ’24−$19.5MDec ’24−$18.8MMar ’25−$17.9MJun ’25−$15.8MSep ’25−$21.7MDec ’25−$19.9MMar ’26−$7.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.3M$19.2M$34.2M$22.6M$30.9M
Operating income−$100.7M−$117.1M−$107.9M−$102.7M−$86.4M
Net income−$101.3M−$108.9M−$98.4M−$86.6M−$74.3M
Operating cash flow−$50.3M$193.6M−$118.1M−$100.4M−$86.1M
Free cash flow−$53.6M$192.4M−$119.3M−$101.3M−$86.1M
Cash$101.1M$52.2M$80.3M$55.5M$80.9M
Debt$0.00none on filenone on filenone on filenone on file
Shares outstanding41.3M41.8M42.3M55.6M56.7M